

Different reactivities of high density lipoprotein₂ subfractions with hepatic lipase

Hiro-Omi Mowri,* Wolfgang Patsch,^{1,*} Louis C. Smith,* Antonio M. Gotto, Jr.,* and Josef R. Patsch*,[†]

Department of Medicine,* Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, and Division of Clinical Atherosclerosis Research,[†] Department of Medicine, University of Innsbruck, A-6020 Innsbruck, Austria

Abstract Human high density lipoproteins₂ (HDL₂) consist of particles that contain both apolipoprotein (apo) A-I and apoA-II (A-I/A-II-HDL₂) and others that contain apoA-I but are devoid of apoA-II (A-I-HDL₂). When postprandial lipemia is pronounced, a fraction of HDL₂ is converted into HDL₃-like particles. These HDL₃ exhibit lower apoA-I/apoA-II ratios than the parent HDL₂, suggesting preferential conversion of A-I/A-II-HDL₂ into HDL₃ (*J. Clin. Invest.* 1984. 74: 2017–2023). Triglyceride transfer from triglyceride-rich lipoproteins to HDL₂ and subsequent lipolysis by hepatic lipase are thought to mediate the conversion of HDL₂ into HDL₃. To understand why A-I/A-II-HDL₂ are preferentially converted into HDL₃, we separated postprandial HDL₂ into A-I-HDL₂ and A-I/A-II-HDL₂ species by immunoaffinity chromatography using a monoclonal antibody for apoA-II, and determined the ability of HDL₂ species *i*) to participate in protein-mediated lipid transfer; and *ii*) to interact with hepatic lipase in vitro. Triglyceride transfer from/to triglyceride-rich lipoproteins was similar for the two HDL₂ species. In contrast, A-I/A-II-HDL₂ were twice as effective as A-I-HDL₂ in liberating hepatic lipase immobilized on HDL₃-Sephadex. Lipolysis of triglycerides by hepatic lipase was 60% higher in postprandial A-I/A-II-HDL₂ than in postprandial A-I-HDL₂. Hydrolysis of phosphatidylcholine by hepatic lipase was threefold higher in A-II-containing HDL₂ when compared with HDL₂ devoid of apoA-II. The different lipolytic rates in HDL₂ subspecies correlated with the size reduction of substrate lipoproteins. Reconstitution of postprandial A-I-HDL₂ with apoA-II enhanced the rate of lipolysis by hepatic lipase to that observed in A-I/A-II-HDL₂. We conclude that it is the interaction with hepatic lipase rather than the rate of triglyceride transfer that results in the preferred conversion of postprandial A-II-containing HDL₂ into HDL₃, and that apoA-II exerts a crucial role in this process.—Mowri, H.-O., W. Patsch, L. C. Smith, A. M. Gotto, Jr., and J. R. Patsch. Different reactivities of high density lipoprotein₂ subfractions with hepatic lipase. *J. Lipid Res.* 1992. 33: 1269–1279.

Supplementary key words apolipoprotein A-I • apolipoprotein A-II • HDL₂

In virtually every major epidemiologic study, a powerful inverse association has been found between coronary artery disease (CAD) and high density lipoprotein (HDL)-cholesterol (1–4). HDL are traditionally divided into two

major subclasses, HDL₂ and HDL₃. As a strong correlation exists between HDL-cholesterol and plasma levels of HDL₂, but not of HDL₃, plasma concentrations of HDL₂ may better reflect the “protective” function of HDL-cholesterol. Even though epidemiologic studies do not always support this view (5), the importance of HDL₂ is suggested by clinicopathological studies (6) and the relationship between prevalence or incidence of CAD and HDL₂ plasma levels as observed in males and females (7). Furthermore, the beneficial effects of high HDL₂ levels are also apparent in an autosomal dominant inherited condition, familial hyperalphacholesterolemia, which reportedly is associated with longevity (8). In these subjects, most of the HDL-cholesterol is found in the HDL₂ fraction, while concentrations of HDL₃ are similar to those in controls (9). Therefore, the mechanisms controlling the plasma levels of HDL₂ are central to our understanding of the inverse relationship between CAD and HDL-cholesterol.

The metabolism of triglyceride-rich lipoproteins (TGRL) is a major determinant of HDL₂ concentrations in blood. The assimilation of TGRL-derived surface material, predominantly phospholipids, by HDL promotes the formation of HDL₂-like particles from HDL₃ (10). Conversely, impaired metabolism of TGRL, as ascertained in the postprandial state, reduces the concentration of HDL₂. When the concentration of TGRL is increased postprandially, cholesteryl esters are translocated from HDL₂ to TGRL in exchange for roughly equimolar amounts of triglycerides (11–14). Triglycerides transferred to HDL are hydrolyzed by hepatic lipase. Dependent on the enrich-

Abbreviations: HDL, high density lipoprotein; VLDL, very low density lipoprotein; TGRL, triglyceride-rich lipoproteins; CAD, coronary artery disease; TG, triglyceride; PL, phospholipid.

¹To whom correspondence should be addressed at: Baylor College of Medicine, Department of Medicine, Mail Station A-601, 6565 Fannin Street, Houston, TX 77030.

ment of postprandial HDL₂, this process may lead to conversion of the larger HDL₂ into smaller HDL₃ (15). In vitro incubation of postprandial triglyceride-enriched HDL with hepatic lipase showed that HDL₃-like particles generated had a two- to threefold lower molar ratio of apoA-I to apoA-II when compared to particles remaining within the HDL₂ flotation range. Furthermore, particles remaining in the HDL₂ flotation range after incubation showed an increased molar ratio of apoA-I to apoA-II when compared with parent HDL₂ (16). This suggested preferential conversion of apoA-II-containing HDL₂ into HDL₃ which could have resulted from enhanced translocation of triglycerides from TGRL to apoA-II-containing HDL₂ or enhanced hydrolysis of core lipids in apoA-II-containing HDL₂ by hepatic lipase. However, shedding of apolipoproteins during lipolysis could have caused changes in the apolipoprotein composition of HDL subclasses as well. To distinguish among these possibilities, we have isolated postprandial HDL₂ containing apoA-II (A-I/A-II-HDL₂) and devoid of apoA-II (A-I-HDL₂) by immunoaffinity chromatography. We have determined the ability of these two HDL₂ species to participate in protein-mediated lipid transfer and to interact with hepatic lipase. We report here that it is not the selective participation in the neutral lipid exchange process of apoA-II-containing HDL₂ but rather their interaction with hepatic lipase that confers specificity to the conversion of apoA-II-containing HDL₂ into HDL₃ (part of this research was presented in abstract form, ref. 17).

METHODS

Blood from fasting subjects was obtained after an overnight fast. Postprandial blood was obtained 6 h after a standardized fatty meal (18). Blood was collected into tubes containing 1.5 mg EDTA/ml of blood, and plasma was separated by centrifugation (1500 g, 20 min, 4°C). For isolation of HDL₂ and HDL₃ zonal ultracentrifugation was used (19). Volume fractions containing HDL₂ were subjected to gel permeation chromatography using Bio-gel A-5M in 2.5 cm × 95 cm columns. Purified lipoprotein fractions were dialyzed against standard buffer containing 0.9% NaCl, 0.3 mM EDTA, 0.01 M Tris-HCl, pH 7.8.

For separation of HDL₂ subfractions containing apoA-I/apoA-II or apoA-I without apoA-II, immunoaffinity chromatography was used (20). Mab 32, a monoclonal anti-apoA-II antibody, was purified from murine ascites fluid (21). After treatment of ascites fluid with Lipoclean (Calbiochem, San Diego, CA) and 50% ammonium sulfate precipitation, anti-apoA-II antibody was solubilized in 10 mM Tris-HCl, pH 7.4, containing 0.15 M NaCl, 1 mM EDTA, and 0.02% NaN₃. After centrifugation at 1000 g for 10 min, the supernate was recycled twice through an HDL₃-Sepharose 4B column, 1.5 × 20 cm, at a flow rate

of 40 ml/h. The HDL₃-Sepharose 4B was prepared from HDL₃ containing 104 mg protein and 10 g of CNBr-activated Sepharose 4B according to the instructions of the manufacturer (Pharmacia, Piscataway, NJ). Nonspecifically bound proteins were removed by washing the column with standard buffer until the A₂₈₀ was less than 0.02 units. Mab directed against apoA-II was eluted from the column with 0.2 M glycine buffer, pH 2.8, containing 1 mM EDTA and 0.02% NaN₃. Four-ml fractions were collected into tubes containing 1.4 ml of 1 M Tris-HCl, pH 8.0. Reactivity of affinity-purified antibodies against HDL₃ was established by ELISA using alkaline phosphatase-conjugated anti-mouse IgG as second antibody.

Affinity-purified Mab 32 was covalently coupled to CNBr-activated Sepharose 4B at a ratio of 9–11 mg per 1 g of gel. The Mab 32-Sepharose 4B was extensively washed with several cycles of 0.1 M NaHCO₃, 0.5 M NaCl, pH 8.0, and 0.1 M Na acetate, 0.5 M NaCl, pH 4.0, followed by 0.2 M glycine, pH 2.8. The gel was then equilibrated in Tris-HCl, pH 7.4, containing 0.02% NaN₃ and stored at 4°C.

For separation of A-I/A-II-HDL₂ and A-I-HDL₂, HDL₂ containing up to 5 mg protein was diluted to a volume of 10 ml with Tris-buffered saline and applied to Mab 32-Sepharose 4B columns (1 × 7 cm) at a flow rate of 8 ml/h. The eluate was recycled twice through the column prior to collecting unbound HDL in 1-ml fractions. After collection of 30 fractions, the elution buffer was changed to 0.2 M glycine buffer, pH 2.8, and 1-ml fractions were collected into tubes containing 0.35 ml of 1 M Tris-HCl, pH 8.0. In larger scale experiments, 10 mg HDL₂-protein was applied to 1.5 × 19 cm columns.

Protein was measured by the method of Lowry et al. (22) using bovine serum albumin as standard. Cholesterol, esterified cholesterol, and triglycerides were determined by enzymatic procedures (23–25). Lipid phosphorus was determined by the procedure of Bartlett (26). For analysis of particle size, HDL fractions were subjected to electrophoresis in 4–30% polyacrylamide gels (27). Apolipoproteins were separated by polyacrylamide gel electrophoresis in 0.1% SDS (28) or by isoelectric focusing (29). Relative abundance of apoA-I and apoA-II was determined by scanning of IEF-gels using a laser densitometer (LKB Ultrascan XL, Pharmacia LKB Biotechnology Inc., Piscataway, NJ) as described (30).

To determine transfer of triglycerides between TGRL and HDL fractions, *d* < 1.006 g/ml lipoproteins, isolated by ultracentrifugation, were labeled with [¹⁴C]triolein according to the method of Simard et al. (31). Ten μCi (89 nmol) of tri[¹⁴C]oleoylglycerol (DuPont, Wilmington, DE) dispersed in 50 μl ethanol, were added to 10 ml plasma, and incubated for 3.5 h at 37°C in the presence of 0.25 mM EDTA and 0.01% NaN₃. TG-rich lipoproteins were then isolated at a density of 1.006 g/ml by ultracentrifugation and further purified by gel permeation chromatography on a Sephadex G-50 column (1 × 15

cm). ^{14}C -labeled VLDL (100 μg TG) was incubated together with HDL fractions and 5,5-dithio-2-nitrobenzoic acid (2 mM) at 37°C in the presence or absence of lipoprotein-deficient plasma (5 mg protein) in 0.05 M phosphate buffer, pH 7.4. The total assay volume was 700 μl . After stopping the reaction by placing the tubes on crushed ice for 15 min, 250 μl saline, 50 μl LDL (6.4 mg protein/ml), 100 μl HDL₂ (5.8 mg protein/ml), and 120 μl of a mixture containing 0.1% dextran sulfate and 1 M MgCl_2 were added. After mixing, tubes were allowed to stand on ice for 15 min prior to centrifugation at 3,500 g for 10 min. Radioactivity in supernates was determined by liquid scintillation counting. Triglyceride exchange activity was calculated by the formula (32):

$$F = \frac{-\ln \left[1 - \frac{C_H}{M_V(S_{V(0)} - S_{Eq})} \right]}{\frac{M_V + M_H}{M_V \cdot M_H} t}$$

where F is the rate of exchange in nmol/h per incubation between VLDL and HDL. M_V is the pool size of triglycerides in VLDL in nmol/incubation, M_H the pool size of cholesteryl ester and triglycerides in HDL in nmol/incubation, C_H is the radioactivity in HDL in counts/min at time t , where t is expressed in hours. $S_{V(0)}$ denotes counts/ M_V (cpm/nmol) at time 0 and S_{Eq} counts/($M_V + M_H$) in cpm/nmol at equilibrium.

Hepatic lipase was isolated and purified from healthy volunteers. They were injected with 2,280 U/m² heparin and blood was obtained 10–15 min after heparin administration. Purification steps included adsorption of the enzyme to Intralipid (Vitrum, Stockholm, Sweden) and affinity chromatography with heparin-Sepharose (Pharmacia, Piscataway, NJ) (33). A stepwise elution with 0.9 M NaCl was used, and enzyme activities were measured in column fractions. Activities of lipoprotein lipase and hepatic lipase were determined according to Huttunen et al. (34), using [^{14}C]triolein-labeled substrate stabilized with gum arabic and an antiserum directed against hepatic lipase as described (15). The specific activity of hepatic lipase preparations averaged 5.7 μmol fatty acids released/min per mg protein. Enzyme preparations contained less than 3% lipoprotein lipase activity as judged by lipolytic activity recovered after precipitation with an antiserum directed against hepatic lipase that has been used previously (15).

For displacement studies with HDL₂ subspecies, hepatic lipase was immobilized to HDL₃-Sepharose by incubating 50 μg of the enzyme preparation with 1 ml packed gel and 0.8 ml of equilibration buffer containing 20 mM Tris-HCl, 0.1 M NaCl, and 1% (g/v) bovine serum albumin at 4°C for 60 min (35). After two washes with buffer, 100- μl aliquots of the gel were incubated with

200 μl equilibration buffer containing various concentrations of A-I- or A-I/A-II-HDL₂ at 4°C for 30 min. Incubation mixtures were centrifuged at 3,500 g for 1 min, and supernates were collected. Pellets were washed with 200 μl of equilibration buffer, and twice with 200 μl of 5 mM deoxycholic acid in 20 mM Tris-HCl, pH 8.5. All supernates were assayed for hepatic lipase activity. For these experiments, a batch of hepatic lipase complexed to HDL₃-Sepharose was divided into aliquots that were used only once to avoid potential effects of deoxycholic acid on the integrity of the matrix.

To determine substrate properties of HDL₂ subspecies, A-I- and A-I/A-II-HDL₂ were incubated with hepatic lipase in 250 μl of 100 mM Tris-HCl, pH 8.0, containing 4% (w/v) bovine serum albumin. After various incubation periods, lipids were extracted (36). [^{14}C]triolein was added to monitor recovery of triglycerides. Lipids were separated by thin-layer chromatography using a modification of the two-step procedure of Macala, Yu, and Ando (37). Plates were developed to half their height with chloroform-methanol-acetic acid-formic acid-water 70:30:12:4:2 (v/v) and then with hexane-diethyl ether-acetic acid 80:20:1 (v/v). After visualization with iodine vapor, lipids were scraped from the plate and extracted three times with chloroform-methanol 2:1 (v/v). Extracts were analyzed for triglycerides, cholesteryl ester, and phosphorus in phospholipids as described above. Fatty acids were measured according to Stajner and Suva (38). To determine the initial rates of fatty acid release, fatty acid concentrations were measured in such incubation mixtures using an enzymatic procedure (Free Fatty Acids Kit, Boehringer Mannheim, Mannheim, Germany).

To increase the triglyceride content of HDL₂ subfractions, HDL₂ (10 mg protein) was incubated with VLDL (0.5 or 2.0 mg protein) and lipoprotein-deficient plasma (20 mg protein/ml) in a volume of 40 ml of 10 mM Tris-HCl, 140 mM NaCl, 1 mM EDTA, 0.02% NaN_3 (w/v), 2 mM dithionitrobenzoic acid, pH 7.4, at 37°C. After an incubation period of 16 h, HDL₂ were isolated by zonal ultracentrifugation, and A-I- and A-I/A-II-HDL₂ were separated by immunoaffinity chromatography and used as substrates for hepatic lipase.

To estimate effects of lipolysis on particle size, postprandial A-I-HDL₂ and A-I/A-II-HDL₂ were labeled by the ICl procedure (39) to a specific activity of 10⁷ cpm/mg protein. Labeled HDL₂ subspecies were incubated with hepatic lipase in incubation mixtures described. After various incubation periods, aliquots of mixtures were analyzed by electrophoresis in 5–20% of polyacrylamide gradients. Gels were dried prior to exposure to X-ray film.

To reconstitute A-I-HDL₂ with apoA-II, A-I-HDL₂ containing 1.5 mg protein was incubated with 0.75 mg apoA-II in 1.5 ml of 10 mM Tris-HCl, pH 7.4, containing 0.15 M NaCl, 0.02% NaN_3 , and 1 mM EDTA at 25°C for 2 h (40). Incubation mixtures were brought to a density




Fig. 1. Analysis of postprandial HDL₂ species by SDS-polyacrylamide gel electrophoresis (A), isoelectric focusing (B), and 4–30% polyacrylamide gel electrophoresis under nondenaturing conditions (C); lanes 1, 2, and 3 are total HDL₂, A-I-HDL₂, and A-I/A-II-HDL₂, respectively. Molecular weight standards are in lanes S.

of 1.21 g/ml by using KBr and ultracentrifuged in an SW 40 rotor (Beckman, Palo Alto, CA) at 40,000 rpm, 10°C for 24 h. The top fraction containing the reconstituted particles was dialyzed and applied to affinity chromatography on Mab 32-Sepharose 4B. The retained fraction was eluted as described before, dialyzed, characterized, and used for incubation studies.

RESULTS

Affinity chromatography using Mab 32-Sepharose 4B was effective in separating postprandial HDL₂ subspecies based on their apoA-II content. As judged by polyacrylamide gel electrophoresis in 0.1% SDS and isoelectric focusing, the unbound fraction was devoid of apoA-II, while the apoA-II content of the retained fraction increased as the dye uptake ratio of A-I/A-II decreased from 11.6 in parent HDL₂ to 5.2 in A-I/A-II-HDL₂ (Fig. 1A and B). A-I- and A-I/A-II-HDL₂ exhibited similar size as

estimated by nondenaturing gradient gel electrophoresis (Fig. 1C). Postprandial A-I/A-II-HDL₂ exhibited a lower content of triglycerides and unesterified cholesterol when compared with postprandial A-I-HDL₂ (Table 1). The phospholipid composition of HDL₂ subspecies was similar. As determined in two preparations, mean percentage contribution of lysophosphatidylcholine, sphingomyelin, phosphatidylcholine, and phosphatidylethanolamine to phospholipids was 0.9, 9.1, 86.8, and 3.2 in A-I-HDL₂ and 1.0, 9.4, 86.7, and 2.9 in A-I/A-II-HDL₂, respectively.

To determine the ability of HDL-subspecies to participate in protein-mediated lipid transfer, translocation of ¹⁴C-labeled triglyceride between labeled VLDL and HDL-subspecies was measured using lipoprotein-deficient plasma as source of transfer activity. In three different HDL preparations, initial rates of triglyceride transfer were virtually the same for the two HDL₂ subspecies (Fig. 2). Using two concentrations of HDL₂ subfractions and incubation periods of 16 h, no significant difference in triglyceride transfer was found in HDL₂ preparations

TABLE 1. Weight percentage chemical composition of postprandial A-I-HDL₂ and A-I/A-II-HDL₂

	Protein	PL	UC	CE	TG
A-I-HDL ₂	38.7 (2.0)	34.0 (1.8)	3.7 (1.3)	17.4 (2.1)	6.6 (2.5)
A-I/A-II-HDL ₂	41.5 (2.9)	32.3 (2.9)	3.0 (0.9) ^a	17.8 (1.4)	5.7 (2.1) ^a

Results are means (SD) of four preparations. PL, phospholipids; UC, unesterified cholesterol; CE, cholesteryl ester; TG, triglycerides.

^a*P* < 0.05.




Fig. 2. Initial rates of triglyceride transfer between triglyceride-rich lipoproteins and A-I- and A-I/A-II-HDL₂. Incubation mixtures contained 100 μ g triglycerides of [¹⁴C]triolein-labeled triglyceride-rich lipoproteins, 25 μ g protein of A-I- (O) or A-I/A-II-HDL₂ (●), and 5 mg protein of lipoprotein-deficient plasma in a total volume of 0.7 ml. The incubation temperature was 37°C. Values are means \pm SD of three different HDL preparations.

obtained from three different subjects (data not shown). Thus, in none of our experiments was the transfer of triglycerides to and from A-I/A-II-HDL₂ greater when compared with A-I-HDL₂.

Bengtsson and Olivecrona (35) previously demonstrated that hepatic lipase binds to HDL that is covalently attached to Sepharose. We reasoned that a matrix containing immobilized enzyme would be suitable for displacement studies of enzyme by various HDL₂ fractions. In control experiments, HDL₂ subspecies labeled in their protein moiety were incubated with hepatic lipase immobilized to the HDL₃ matrix using the conditions applied for subsequent displacement studies. There was no difference in the proportions of HDL-associated radioactivity between A-I-HDL₂ and A-I/A-II-HDL₂ which was recovered in the various elution steps (Table 2). To determine the interaction of postprandial HDL subspecies with hepatic lipase, the ability of these fractions to

displace hepatic lipase immobilized to HDL₃-Sepharose was measured at increasing concentrations (Table 3). On the average, A-I/A-II-HDL₂ were about twice as effective as A-I-HDL₂ to liberate immobilized enzyme ($P < 0.05$, two-way analysis of variance). In these experiments, effects of HDL₂ species and deoxycholic acid on apparent activity of hepatic lipase in the respective supernates were taken into account. In other control experiments, enzyme activity was measured in the presence of HDL₂ species present at concentrations representative for the various supernates (Tables 2 and 3). At the highest HDL concentration used in Table 3, apparent lipolytic activity was reduced to 91% and 84% of control by A-I- and A-I/A-II-HDL₂, respectively. Deoxycholic acid, present in supernate III, did not alter lipolytic activity under our assay conditions. Thus, consistent with our earlier studies (15), HDL₂ had only minor inhibitory effects on apparent lipolytic activity which were used to correct the data shown in Table 3.

To directly compare substrate properties of A-I- and A-I/A-II-HDL₂, lipolysis was measured after incubation of the two HDL₂ subspecies with hepatic lipase. Initially, postabsorptive HDL₂ subfractions were incubated for 20 h. Lipolysis of triglycerides and phosphatidylcholine in A-I/A-II-HDL₂ was 68 and 43%, respectively, higher than in A-I-HDL₂ as determined by mass measurements before and after incubation. A 4-h incubation experiment with postprandial HDL₂ subfractions clearly demonstrated the superior substrate properties of A-I/A-II-HDL₂ (Table 4). In our separate preparations, lipolysis of triglycerides in postprandial A-I/A-II-HDL₂ by hepatic lipase was $159 \pm 5.25\%$ (mean \pm SD, $P < 0.02$) of that in postprandial A-I-HDL₂. Hydrolysis of phosphatidylcholine measured in three different HDL preparations was about threefold higher in A-I/A-II-HDL₂ than in A-I-HDL₂ (Table 4). To compare substrate properties of HDL₂ subspecies more rigorously, initial rates of fatty acid liberation were measured over a 4-h incubation period. At all time points, mean values of fatty acids

TABLE 2. Distribution of ¹²⁵I-labeled A-I-HDL₂ and ¹²⁵I-labeled A-I/A-II-HDL₂ in supernates after incubation with hepatic lipase immobilized to HDL₃-Sepharose

HDL ₂ -Species	HDL ₂ -Protein mg/incubation	Supernate I	Supernate II	Supernate III	Total Recovery
					%
		% of radioactivity applied			
A-I-HDL ₂	0.16	64.3	19.9	13.7	97.9
A-I-HDL ₂	0.32	65.4	19.4	13.0	97.8
A-I/A-II-HDL ₂	0.16	64.5	21.8	14.6	100.9
A-I/A-II-HDL ₂	0.32	67.3	22.1	11.7	101.1

Aliquots of 0.1 ml of HDL₃-Sepharose containing immobilized hepatic lipase were incubated with ¹²⁵I-labeled HDL₂ species at two concentrations each in a total volume of 0.3 ml at 4°C for 30 min. Radioactivity was determined in supernates. Supernate I was obtained by centrifugation of the incubation mixture; supernate II was obtained after washing the pellet with equilibration buffer; and supernate III was obtained after washing the pellet of the first wash with 5 mM deoxycholic acid (see Methods).

TABLE 3. Liberation of hepatic lipase activity immobilized to HDL₃-Sepharose by A-I-HDL₂ and A-I/A-II-HDL₂

HDL ₂ Subfraction (protein/incubation)	Lipolytic Activity Liberated		
	Supernate I	Supernate II	Supernate III
	% of activity recovered		
A-I-HDL ₂			
0.16 mg	1.1	0.1	98.8
0.32 mg	3.0	2.1	95.0
0.64 mg	8.8	4.0	87.2
A-I/A-II-HDL ₂			
0.16 mg	2.8	1.9	95.3
0.32 mg	6.4	4.1	89.5
0.64 mg	16.5	5.8	77.7

Hepatic lipase was bound to HDL₃-Sepharose; 0.1-ml aliquots of the matrix were incubated with increasing doses of postabsorptive HDL₂ species in a total volume of 0.3 ml at 4°C for 30 min. Enzyme activity was then determined in supernates obtained by centrifugation. Supernate I was obtained by centrifugation of the incubation mixture; supernate II was obtained after washing the pellet with incubation buffer; and supernate III was obtained by a second wash of the pellet with 5 mM deoxycholic acid. Lipolytic activities in the respective supernates were corrected for effects of the HDL₂ species on apparent lipolytic activity under our assay conditions. Results are expressed as percentage of enzyme activity released from the matrix and are the means of duplicate determinations which differed by less than 15%. Lipolytic activity of the various incubation mixtures which was recovered in the three supernates was 444.1 ± 43.5 nmol/h (mean ± SD).

released were higher in incubation mixtures containing A-I/A-II-HDL₂ (Fig. 3, $P < 0.001$, analysis of covariance, equality of slopes test). Furthermore, the velocity of fatty acid release was greater for A-I/A-II-HDL₂ at all substrate concentrations studied (Fig. 4, $P < 0.001$, analysis of covariance, equality of slopes test).

Lipolysis of surface phospholipids and core triglycerides by hepatic lipase results in reduction of particle mass and size. To relate differences in substrate properties of A-I- and A-I/A-II-HDL₂ to size changes, labeled A-I- and A-I/A-II-HDL₂ were incubated with hepatic lipase and the sizes of parent and product lipoproteins were estimated from autoradiograms of nondenaturing polyacrylamide gels. As shown in Fig. 5, migration distances of parent and control incubated HDL₂ subspecies were identical, but greater increases in mobility were noted in A-I/A-II-HDL₂ after incubation with hepatic lipase for 4 or 16 h. Stokes radii of A-I-HDL₂ estimated from standards were 11.1, 11.0, and 10.8 nm at the 0, 4 and 16 h time points. The respective values for A-I/A-II-HDL₂ were 11.2, 10.9, and 10.6 nm. In addition to the major band representing the respective HDL₂ subspecies, faint bands with an apparent molecular mass of less than 67 kDa are visible in this figure. These bands, which could have represented free apolipoproteins, did not dramatically increase during lipolysis of either HDL subspecies, suggesting that only minor, if any, apolipoprotein shedding occurred as a result of lipolysis.

TABLE 4. Hydrolysis of triglycerides and phosphatidylcholine in A-I-HDL₂ and A-I/A-II-HDL₂ by hepatic lipase

	Triglyceride Hydrolyzed ^a	Phosphatidylcholine Hydrolyzed ^b
	nmol/incubation	
A-I-HDL ₂	4.65 ± 0.95	1.33 ± 0.34
A-I/A-II-HDL ₂	7.38 ± 1.69 ^c	3.92 ± 0.31 ^d

^aResults are means ± SD of four HDL preparations and show the decrease of triglycerides in nmol/incubation. Incubation mixtures contained 19 μg HDL-triglyceride in 250 μl. Incubation was for 4 h at 28°C.

^bResults are means ± SD of three different preparations and show the decrease of phosphatidylcholine in nmol/incubation mixture. Incubation mixtures contained 100 μg HDL-phospholipid and 7 μg hepatic lipase in 250 μl. Incubation was for 4 h at 28°C.

^c $P < 0.02$, Mann-Whitney test.

^d $P < 0.05$, Mann-Whitney test.

To determine whether the distinctiveness in substrate properties of HDL₂ subspecies is modulated by their triglyceride content, the cores of postabsorptive HDL₂ subfractions were enriched with triglycerides in vitro through the neutral lipid transfer reaction. The changes in chemical composition induced are shown in Table 5. At the same substrate concentration of HDL-triglycerides, initial rates of fatty acid release were higher in incubation mixtures containing A-I/A-II-HDL₂, irrespective of the enrichment with triglycerides over the range studied (Table 6, $P < 0.05$, two-way analysis of variance). Thus, the difference in substrate properties was apparent over a threefold range in the TG/PL ratio. In contrast, TG transfer rates were not different for A-I- and A-I/A-II-HDL₂ subspecies with similar core composition.

As the major qualitative difference between postprandial HDL₂ subspecies was their apoA-II content (Table 1 and Fig. 1A and B), a role of apoA-II in enhancing sub-




Fig. 3. Time course of fatty acid liberation from A-I- and A-I/A-II-HDL₂ by hepatic lipase. A-I- (○) and A-I/A-II-HDL₂ (●) (4 μg triglyceride) were incubated with 1.4 μg of hepatic lipase in 50 μl of 100 mM Tris-HCl, pH 8.0, containing 4% bovine serum albumin (w/v).




Fig. 4. Effect of substrate concentration on rates of fatty acid liberation from A-I- and A-I/A-II-HDL₂ by hepatic lipase. A-I- (○) and A-I/A-II-HDL₂ (●) were incubated at various concentrations for 1 h with 1.4 µg of hepatic lipase in 50 µl of 100 mM Tris-HCl, pH 8.0, containing 4% bovine serum albumin (w/v). Means ± SD of triplicate determinations are shown.

strate properties was suggested. We therefore reconstituted A-I/A-II-HDL₂ from postprandial A-I-HDL₂ and apoA-II. The apoA-I/apoA-II dye uptake ratio was 4.8 in reconstituted particles as compared to 5.8 in postprandial A-II-containing HDL₂, and no major changes in size were observed upon reconstitution as judged by gradient gel electrophoresis (Fig. 6). In reconstituted particles, the protein content was increased to 45.6% compared to 39.3% and 40.1% in A-I- and A-I/A-II-HDL₂ isolated from this subject. Composition of lipids and main phospholipids was similar to that of the A-I-HDL₂ used for reconstitution (data not shown). Association of A-I-HDL₂ with apoA-II clearly enhanced its substrate properties as determined by mass measurements of triglycerides and fatty acids (Table 7). Similar results were obtained with a




Fig. 5. Effect of lipolysis by hepatic lipase on size of substrate particle as determined by autoradiography of 5–20% polyacrylamide gels. ¹²⁵I-labeled A-I- and ¹²⁵I-labeled A-I/A-II-HDL₂ (4 µg triglyceride) were incubated with or without hepatic lipase. Lane 1, no incubation; lane 2, 4 h incubation with 3 µg of enzyme; lane 3, 16 h incubation with 3 µg of enzyme each added at 0 and 8 h of incubation; lane 4, 16 h incubation without enzyme.

different preparation of postprandial A-I-HDL₂ reconstituted with apoA-II.

DISCUSSION

Our main conclusion is that the preferential conversion of apoA-II-containing HDL₂ into HDL₃ results from enhanced interaction of hepatic lipase with A-I/A-II HDL₂ and not from enhanced triglyceride transfer from TGRL

TABLE 5. Chemical composition of postabsorptive HDL₂ subspecies before and after enrichment with triglycerides in vitro

	Protein	PL	UC	CE	TG	CE + TG	TG/CE + TG	TG/PL
Postabsorptive								
A-I-HDL ₂	41.4	29.5	3.4	21.7	4.1	25.8	0.159	0.139
A-I/A-II-HDL ₂	46.6	26.5	2.6	19.6	4.7	24.3	0.193	0.177
Triglyceride-enriched (a)								
A-I-HDL ₂	40.1	30.8	3.5	16.3	9.3	25.6	0.363	0.302
A-I/A-II-HDL ₂	43.1	29.0	2.7	16.1	9.2	25.3	0.364	0.317
Triglyceride-enriched (b)								
A-I-HDL ₂	38.3	30.0	1.2	16.9	13.6	30.5	0.446	0.453
A-I/A-II-HDL ₂	41.3	30.2	1.0	16.7	10.8	27.5	0.393	0.358

Results are weight percentages and represent means of duplicate measurements. PL, phospholipids; UC, unesterified cholesterol; CE, cholesteryl ester; TG, triglycerides. Postabsorptive HDL₂ were enriched with triglycerides by incubating lipoprotein-deficient plasma with the HDL₂ and VLDL at a protein weight ratio of 20 and 5 in (a) and (b), respectively. The resulting triglyceride-enriched HDL₂ was isolated by zonal ultracentrifugation, and A-I-HDL₂ and A-I/A-II-HDL₂ were separated by immunoaffinity chromatography (see Methods).

TABLE 6. Release of fatty acids by hepatic lipase in postabsorptive triglyceride-enriched HDL₂ subspecies and triglyceride transfer between these subspecies and triglyceride-rich lipoproteins

HDL ₂ Fraction	Fatty Acids Released	Triglyceride Transferred
nmol/h/incubation		
Postabsorptive		
A-I-HDL ₂	4.2	0.69
A-I/A-II-HDL ₂	7.1	0.68
Triglyceride-enriched (a)		
A-I-HDL ₂	2.8	0.74
A-I/A-II-HDL ₂	6.0	0.78
Triglyceride-enriched (b)		
A-I-HDL ₂	3.9	0.87
A-I/A-II-HDL ₂	5.8	0.82

Postabsorptive HDL₂ was enriched with triglycerides by incubating lipoprotein-deficient plasma with HDL₂ and VLDL at a protein weight ratio of 20 or 5 in (a) and (b), respectively. Hepatic lipase activity was measured by incubating 4 μg of HDL₂ triglyceride and 3 μg of enzyme in 50 μl at 28°C for 60 min. For TG-transfer analysis, each HDL₂ subfraction (25 μg protein) was incubated at 37°C for 4 h with 100 μg triglyceride of [¹⁴C]triolein-labeled triglyceride-rich lipoproteins and 5 mg protein of lipoprotein-deficient plasma in a volume of 700 μl. Results are means of duplicate determinations which differed by less than 15%.

to A-I/A-II-HDL₂ during the postprandial phase. This conclusion is based on the following findings: *i*) Postprandial apoA-II-containing HDL₂ contained less triglycerides in their core when compared with postprandial HDL₂ devoid of apoA-II (Table 1). *ii*) The rate of triglyceride transfer from TGRL to A-I/A-II-HDL₂ never exceeded the rate of transfer to A-I-HDL₂ in *in vitro* experiments (Fig. 2). *iii*) A-I/A-II-HDL₂ were more effective in liberating hepatic lipase immobilized to HDL₃-Sephadex (Table 3). *iv*) Lipolysis of triglycerides and phospholipids in postprandial A-I/A-II-HDL₂ was significantly higher than in postprandial A-I-HDL₂ (Table 4); this difference was also

observed in initial rates of fatty acid release (Fig. 3) and was apparent at all substrate concentrations tested (Fig. 4). Furthermore, differences in substrate properties were reflected in commensurate reductions of particle size (Fig. 5). *v*) Reconstitution of postprandial A-I-HDL₂ with apoA-II enhanced its substrate properties for hepatic lipase (Table 7).

Consistent with our data for postprandial HDL, A-I/A-II-HDL₂ contained less triglycerides than A-I-HDL₂ in the postabsorptive state (41). *In vitro* studies with reconstituted HDL suggest that an increased content of triglycerides and free cholesterol decreases the ability of HDL to accept cholesteryl esters transferred by cholesteryl ester transfer protein (CETP) (42). However, greater than twofold changes in the relative abundance of triglycerides and free cholesterol were required in these model lipoproteins to demonstrate the inhibition of transfer. Using a solid phase radioimmunoassay for measurement of CETP mass, Marcel et al. (43) found a significant correlation of CETP with apoA-I, apoE, HDL-cholesterol, and HDL-triglyceride while no correlation existed with apoA-II. Furthermore, CETP was present mostly in small HDL₃ particles, known to contain primarily apoA-I (20). These studies argue as well against a specific interaction between apoA-II and CETP.

While our results suggest a role of apoA-II in the interaction of HDL₂ species with hepatic lipase, apoA-II is not obligatory for hepatic lipase action as significant lipolysis of triglycerides was observed in A-I-HDL₂ albeit at a lesser rate. The enhanced liberation of hepatic lipase from HDL₃-Sephadex by A-I/A-II-HDL₂ suggests that apoA-II facilitates the association of the enzyme with its substrate. A role of apoA-II in the activation of hepatic lipase is also supported by *in vivo* data, as the concentration of A-I/A-II-HDL₂ was found to be increased in hepatic lipase deficiency, while the concentration of A-I/A-II-HDL₃ was

Fig. 6. Isoelectric focusing gels (A) and 4–30% polyacrylamide gradient gels (B) of postprandial A-I-HDL₂ reconstituted with apoA-II (lane 1), A-I-HDL₂ used for reconstitution (lane 2), and A-I/A-II-HDL₂ obtained from the same subject (lane 3). Molecular weight markers are shown in lanes S.




TABLE 7. Hepatic lipase-catalyzed hydrolysis of triglycerides in native postprandial HDL₂ subspecies and in A-I-HDL₂ reconstituted with apoA-II

HDL ₂ Fraction	Decrease of Triglycerides	Fatty Acid Increase
	<i>nmol/incubation</i>	
A-I/A-II-HDL ₂	5.5 ± 1.1 ^c	19.9 ± 4.1
A-I-HDL ₂	3.4 ± 0.3 ^{a,b}	15.0 ± 3.6 ^c
A-I-HDL ₂ reconstituted with apoA-II	6.2 ± 1.2 ^b	22.3 ± 1.2 ^c

Average triglyceride content of incubation mixtures was 17, 16, and 15 nmol triglycerides for assays containing A-I/A-II-, A-I-, and A-I-HDL₂ reconstituted with apoA-II, respectively. Incubation was at 28°C for 4 h. Results are means ± SD of triplicate determinations.

^{a,b,c}Pairs differing from each other ($P < 0.05$, analysis of variance).

decreased (44). Previous in vitro studies on the effect of apoA-II on hepatic lipase activity are contradictory in that both specific stimulation (45) and nonspecific inhibition (46–48) of enzyme activity by apoA-II have been reported. Some studies used artificial substrates to determine effects of apoA-II on hepatic lipase activity (45, 48). Shinomiya et al. (46) used tri[³H]oleoylglycerol-labeled HDL₂ that was reconstituted with various amounts of apoA-II, to show an inhibitory effect of apoA-II on lipolysis of triglycerides by hepatic lipase. It is possible that lack of discrimination in apoA-II enrichment between A-I- and A-I/A-II-HDL has confounded these results. Inhibition of hepatic lipase activity may become evident when the substrate surface is saturated with apolipoproteins (46, 48). Such an inhibition is nonspecific and can also be demonstrated with synthetic lipid binding model peptides (33). Saturation of the substrate surface with apolipoproteins changes the interfacial properties by reducing the availability of substrate. Clearly, additional experiments in model lipoproteins are necessary to define the stoichiometry of apoA-II to lipids and other apoproteins required for binding and/or activation of hepatic lipase.

A number of studies indicate that A-I- and A-I/A-II-HDL are metabolically distinct and fulfill different functions. Clinical studies showed that drug treatment alters the proportion of A-I-HDL and A-I/A-II-HDL (47). The well-established male–female difference in plasma levels of HDL₂ reflects increased concentrations of apoA-I-HDL in HDL₂ of females (49). A cholesterol-rich diet also alters the partition of A-I and A-I/A-II particles between HDL₂ and HDL₃ (H. Mowri and W. Patsch, unpublished observation). Particles containing A-I may be the physiologic acceptor of cellular cholesterol (50). Our studies further specify functional differences between A-I- and A-I/A-II-HDL. The preferential conversion of apoA-II-containing HDL₂ to HDL₃ during postprandial lipemia may provide the volume necessary to accommodate cholesteryl esters synthesized de novo by LCAT. Conversely, A-I/A-II-HDL₃ may be converted into larger HDL₂-like particles through assimilation of surface components liberated during lipolysis of TGRL. ApoA-II-containing

HDL could thus represent a shuttle in going from HDL₂ to HDL₃ via lipid exchange with TGRL and lipolysis by hepatic lipase and from HDL₃ to HDL₂ through acquisition of surface components. ■■

The authors wish to thank I. Y. Chen, I. Thandi, and S. Helbing for expert technical assistance. This work was supported by grants HL-27341 and HL-41199 from the National Institutes of Health and by grant S-46/06 from the Austrian Fonds zur Foerderung der Wissenschaftlichen Forschung.

Manuscript received 23 September 1991 and in revised form 23 April 1992.

REFERENCES

1. Miller, G. J., and N. E. Miller. 1975. Plasma high density lipoprotein concentration and development of ischemic heart disease. *Lancet*. i: 16–19.
2. Rhoads, G. G., G. L. Gulbrandsen, and A. Kagan. 1976. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. *N. Engl. J. Med.* **294**: 293–298.
3. Tyroler, H. A. 1980. Epidemiology of plasma high-density lipoprotein cholesterol levels. *Circulation*. **62(Suppl. IV)**: IV-1–IV-3.
4. Gordon, D. J., J. I. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, Jr., S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation*. **79**: 8–15.
5. Stampfer, M. J., F. M. Sacks, S. Salvini, W. C. Willet, and C. H. Hennekens. 1991. A prospective study of cholesterol, apolipoprotein, and risk of myocardial infarction. *N. Engl. J. Med.* **325**: 373–381.
6. Miller, N. E., F. Hammett, S. Saltissi, S. Rao, H. VonZeller, J. Coltant, and B. Lewis. 1981. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. *Br. Med. J.* **282**: 1741–1744.
7. Nichols, A. V. 1967. Human serum lipoproteins and their interrelationships. *Adv. Biol. Med. Phys.* **11**: 110–158.
8. Glueck, C. J., P. Gartside, R. W. Fallat, J. Sielski, and P. M. Steiner. 1976. Longevity syndromes: familial hypobeta- and familial hyperalphalipoproteinemia. *J. Lab. Clin. Med.* **88**: 941–957.
9. Patsch, W. E. Kuisk, J. Glueck, and G. Schonfeld. 1981. Lipoproteins in familial hyperalphalipoproteinemia. *Arteriosclerosis*. **1**: 156–161.

10. Patsch, J. R., A. M. Gotto, Jr., T. Olivecrona, and S. Eisenberg. 1978. Formation of high density lipoprotein₂-like particles during lipolysis of very low density lipoproteins in vitro. *Proc. Natl. Acad. Sci. USA*. **75**: 4519-4523.
11. Barter, P. J., G. J. Hopkins, and G. D. Calvert. 1982. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. *Biochem. J.* **208**: 1-7.
12. Morton, R. E., and D. B. Zilversmit. 1982. Interrelationship of lipids transferred by the lipid transfer protein isolated from human lipoprotein-deficient plasma. *J. Biol. Chem.* **258**: 11751-11757.
13. Albers, J. J., J. H. Tollefson, C-H. Chen, and A. Steinmetz. 1984. Isolation and characterization of human plasma lipid transfer proteins. *Arteriosclerosis*. **4**: 49-58.
14. Tall, A. R. 1986. Plasma lipid transfer proteins. *J. Lipid Res.* **27**: 361-367.
15. Patsch, J. R., S. Prasad, A. M. Gotto, Jr., and W. Patsch. 1987. High density lipoprotein₂: relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. *J. Clin. Invest.* **80**: 341-347.
16. Patsch, J. R., S. Prasad, A. M. Gotto, Jr., and G. Bengtsson-Olivecrona. 1984. Postprandial lipemia. A key for the conversion of high density lipoprotein₂ into high density lipoprotein₃ by hepatic lipase. *J. Clin. Invest.* **74**: 2017-2023.
17. Mowri, H. O., W. Patsch, L. C. Smith, A. M. Gotto, Jr., and J. R. Patsch. 1990. Different reactivities of high density lipoprotein₂ subfractions with hepatic lipase. *Arteriosclerosis*. **10**: 782a.
18. Patsch, J. R., J. B. Karlin, L. W. Scott, L. C. Smith, and A. M. Gotto, Jr. 1983. Inverse relationship between blood levels of high density lipoproteins₂ and magnitude of postprandial lipemia. *Proc. Natl. Acad. Sci. USA*. **80**: 1449-1453.
19. Patsch, W., G. Schonfeld, A. M. Gotto, Jr., and J. R. Patsch. 1980. Characterization of human high density lipoproteins by zonal ultracentrifugation. *J. Biol. Chem.* **255**: 3178-3185.
20. Cheung, M. C., and J. J. Albers. 1984. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing A-I and A-II and particles containing A-I but no A-II. *J. Biol. Chem.* **259**: 12201-12209.
21. Silberman, S. R., F. Bernini, J. T. Sparrow, A. M. Gotto, Jr., and L. C. Smith. 1987. Monoclonal antibodies as probes of high-density lipoprotein structure: identification and localization of a lipid-dependent epitope. *Biochemistry*. **26**: 5833-5843.
22. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**: 265-275.
23. Patsch, W., S. Sailer, and H. Braunsteiner. 1976. An enzymatic method for the determination of the initial rate of cholesterol esterification in human plasma. *J. Lipid Res.* **17**: 182-185.
24. Siedel, J., E. Hagele, J. Ziegenhorn, and A. W. Wahlefeld. 1983. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. *Clin. Chem.* **29**: 1075-1080.
25. Nagele, U., E. O. Hagele, G. Sauer, E. Wiedermann, P. Lehmann, A. W. Wahlefeld, and W. Gruber. 1984. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. *J. Clin. Chem. Clin. Biochem.* **22**: 165-174.
26. Bartlett, G. R. 1959. Phosphorus assay in column chromatography. *J. Biol. Chem.* **234**: 466-468.
27. Blanche, P. J., E. L. Gong, T. Forte, and A. V. Nichols. 1981. Characterization of human high density lipoproteins by gradient gel electrophoresis. *Biochim. Biophys. Acta.* **381**: 233-241.
28. Neville, D. M. 1971. Molecular weight determination of protein dodecyl complexes by gel electrophoresis in a discontinuous buffer system. *J. Biol. Chem.* **246**: 6328-6334.
29. Warnick, G. R., C. Mayfield, J. J. Albers, and W. R. Hazzard. 1979. Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3. *Clin. Chem.* **25**: 279-284.
30. Patsch, W., K. Kim, W. Wiest, and G. Schonfeld. 1980. Effects of sex hormones on rat lipoproteins. *Endocrinology*. **107**: 1085-1094.
31. Simard, G., B. Perret, S. Durand, Z. Collet, H. Chap, and L. Douste-Blazy. 1989. Phosphatidylcholine and triacylglycerol hydrolysis in HDL as induced by hepatic lipase: modulation of the phospholipase activity by changes in the particle surface or in the lipid core. *Biochim. Biophys. Acta.* **1001**: 225-233.
32. Groener, J. E., R. W. Pelton, and G. M. Kostner. 1986. Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. *Clin. Chem.* **32**: 283-286.
33. Ehnholm, C., and T. Kuusi. 1986. Preparation, characterization, and measurement of hepatic lipase. *Methods Enzymol.* **129**: 716-738.
34. Huttunen, J. K., C. Ehnholm, P. K. T. Kinnunen, and E. A. Nikkila. 1975. An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasma. *Clin. Chim. Acta.* **63**: 335-347.
35. Bengtsson, G., and T. Olivecrona. 1980. The hepatic heparin releasable lipase binds to high density lipoproteins. *FEBS Lett.* **119**: 290-292.
36. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. *J. Biol. Chem.* **226**: 497-509.
37. Macala, L. J., R. K. Yu, and S. Ando. 1983. Analysis of brain lipids by high performance thin-layer chromatography and densitometry. *J. Lipid Res.* **24**: 1243-1250.
38. Stajner, A., and J. Suva. 1977. The determination of nonesterified fatty acids in blood serum using a stable cupric reagent. *J. Clin. Chem. Clin. Biochem.* **15**: 513-514.
39. McFarlane, A. S. 1958. Efficient trace-labeling of proteins with iodine. *Nature (London)* **182**: 53-57.
40. Van Tornout, P., H. Caster, M-J. Lievens, M. Rosseneu, and G. Assmann. 1981. In vitro interaction of human HDL with human apolipoprotein A-II. *Biochim. Biophys. Acta.* **663**: 630-636.
41. James, R. W., A. Proudfoot, and D. Pometta. 1989. Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. *Biochim. Biophys. Acta.* **1002**: 292-301.
42. Sparks, D. L., and P. H. Pritchard. 1989. Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: effect of HDL lipid and apoprotein content. *J. Lipid Res.* **30**: 1491-1498.
43. Marcel, Y. L., R. McPherson, M. Hogue, H. Czarnecka, Z. Zawadzki, P. K. Weech, M. E. Whitlock, A. R. Tall, and R. W. Milne. 1990. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. *J. Clin. Invest.* **85**: 10-17.
44. Cheung, M. C., and A. C. Wolf. 1989. In vitro transformation of apoA-I-containing lipoprotein subpopulations: role of lecithin:cholesterol acyltransferase and apoB-containing lipoproteins. *J. Lipid Res.* **30**: 499-509.
45. Jahn, C. E., J. C. Osborne, Jr., E. J. Schaefer, and H. B.

- Brewer, Jr. 1983. Activation of the enzymic activity of hepatic lipase by apolipoprotein A-II. Characterization of a major component of high density lipoprotein as the activating plasma component in vitro. *Eur. J. Biochem.* **131**: 25-29.
46. Shinomiya, M., N. Sasaki, R. L. Barnhart, K. Shirai, and R. L. Jackson. 1982. Effect of apolipoproteins on the hepatic lipase-catalyzed hydrolysis of human plasma high density lipoprotein₂-triacylglycerols. *Biochim. Biophys. Acta.* **713**: 292-299.
47. Atmeh, R. F., J. Shepherd, and C. J. Packard. 1983. Subpopulations of apolipoprotein A-I in human high density lipoproteins: their metabolic properties and response to drug therapy. *Biochim. Biophys. Acta.* **751**: 175-188.
48. Kubo, M., Y. Matsuzawa, S. Tajima, K. Ishikawa, A. Yamamoto, and S. Tarui. 1981. ApoA-I and apoA-II inhibit hepatic triglyceride lipase from human postheparin plasma. *Biochem. Biophys. Res. Commun.* **100**: 261-266.
49. Ohta, T., S. Hattori, S. Nishiyama, and I. Matsuda. 1988. Studies on the lipid and apolipoprotein compositions of two species of apoA-I-containing lipoproteins in normolipidemic males and females. *J. Lipid Res.* **29**: 721-728.
50. Castro, G. R., and C. J. Fielding. 1988. Early incorporation of cell-derived cholesterol into pre- β -migrating high-density lipoprotein. *Biochemistry.* **27**: 25-29.